PBM
Psyence BiomedicalยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PBM
Psyence Biomedical Ltd.
A life sciences biotechnology company focusing on natural psychedelics
121 Richmond Street West, Penthouse Suite 1300, Toronto, Ontario M5H 2K1
--
Psyence Biomedical Ltd. was incorporated as a company under the laws of Ontario, Canada on June 29, 2023. The company is a life science biotechnology company focused on natural hallucinogens. The Psyence Biomed division works with natural psilocybin products to heal psychological trauma and its mental health consequences in the context of palliative care. The company is committed to the development of advanced natural psilocybin products for clinical research and development. The company's main divisions, Psyence Production, Psyence Therapeutics and Psyence Function, operate in Canada, the United Kingdom, Southern Africa, Australia and the United States.
Company Financials
EPS
PBM has released its 2022 Q2 earnings. EPS was reported at 0.07, versus the expected 0, beating expectations. The chart below visualizes how PBM has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
